DRUG COMPANIES COULD PAY EXTRA FOR THIRD-PARTY REVIEW UNDER HOUSE FDA REFORM BILL; HR 3199 HAS A MODERATE TONE, SIMILAR TO LATEST SENATE BILL
Pharmaceutical companies would have the option of paying extra for third-party reviews and inspections under FDA reform legislation (HR 3199) introduced by Rep. Burr (R-N.C.) March 29.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth